Executive stock sale by PTC Therapeutics (PTCT) Chief Medical Officer

Rhea-AI Filing Summary

PTC Therapeutics executive Lee Scott Golden reported an open-market stock sale. On March 5, 2026, the company’s EVP & Chief Medical Officer sold 10,000 shares of PTC Therapeutics common stock at a price of $63.38 per share.

The sale was executed under a written Rule 10b5-1 trading plan that Golden adopted on December 4, 2025. After this transaction, Golden directly owns 79,944 shares of PTC Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Golden Lee Scott

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		S(1)		10,000	D	$63.38	79,944	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 4, 2025.

	/s/ Avraham S. Adler, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lee Scott Golden report at PTC Therapeutics (PTCT)?

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, reported selling 10,000 shares of common stock in an open-market transaction at $63.38 per share. The transaction was executed under a pre-established Rule 10b5-1 trading plan.

How many PTC Therapeutics (PTCT) shares did the executive sell and at what price?

Lee Scott Golden sold 10,000 shares of PTC Therapeutics common stock at $63.38 per share. This was an open-market sale reported on a Form 4 insider filing and carried out pursuant to a written Rule 10b5-1 trading plan.

How many PTC Therapeutics (PTCT) shares does Lee Scott Golden own after the sale?

Following the reported sale, Lee Scott Golden directly owns 79,944 shares of PTC Therapeutics common stock. This post-transaction holding reflects his remaining direct ownership after selling 10,000 shares in an open-market transaction executed under a Rule 10b5-1 plan.

Was the PTC Therapeutics (PTCT) insider sale made under a Rule 10b5-1 plan?

Yes. The sale was effected pursuant to a written Rule 10b5-1 trading plan adopted by Lee Scott Golden on December 4, 2025. Such plans pre-schedule trades, helping insiders systematically sell shares over time under predetermined conditions.

What role does Lee Scott Golden hold at PTC Therapeutics (PTCT)?

Lee Scott Golden serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics. His Form 4 filing reports his personal open-market sale of 10,000 common shares at $63.38 per share, executed under a written Rule 10b5-1 plan.

When did the reported PTC Therapeutics (PTCT) insider stock sale occur?

The insider stock sale occurred on March 5, 2026. On that date, EVP & Chief Medical Officer Lee Scott Golden sold 10,000 shares of PTC Therapeutics common stock at $63.38 per share in an open-market transaction under a Rule 10b5-1 plan.